UnipharDUB:UPR +0.66%82 ROE % is 17.29% as of Dec. 2025, which is 3% above its 10-year median of 16.85. GuruFocus rates DUB:UPR with a GF Score™ of 82/100 and a GF Value™ of €3.64 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 115 Medical Distribution companies, Uniphar ranks better than 75.65% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Uniphar's annualized net income for the quarter that ended in Dec. 2025 was €67 Mil. Uniphar's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was €389 Mil. Therefore, Uniphar's annualized ROE % for the quarter that ended in Dec. 2025 was 17.29%.
The historical rank and industry rank for Uniphar's ROE % or its related term are showing as below:
DUB:UPR'
s ROE % Range Over the Past 10 Years
Min: 12.67 Med: 16.85 Max: 23.26
Current: 12.99
During the past 10 years, Uniphar's highest ROE % was 23.26%. The lowest was 12.67%. And the median was 16.85%.
DUB:UPR's ROE % is ranked better than 75.65% of 115
companies
in the Medical Distribution industry
Industry Median: 7.1
vs DUB:UPR: 12.99
Uniphar (DUB:UPR) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Uniphar ROE % Related Terms
Uniphar ROE % Historical Data
* Premium members only.
The historical data trend for Uniphar's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Uniphar's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Uniphar ROE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Uniphar's ROE % distribution charts can be found below:
* The bar in red indicates where Uniphar's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Uniphar (DUB:UPR) has a ROE % of 17.29% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Uniphar and its competitors. This is near median its historical median of 16.85. Over the past decade, Uniphar's ROE % has ranged from 12.67 to 23.26. According to the industry distribution chart, Uniphar ranks #28 out of 115 companies in the Medical Distribution industry, placing it in the top 24.3%.
Is Uniphar's ROE % too high?
Uniphar's current ROE % of 17.29% is near median its 10-year median of 16.85. Over the past 10 years, this metric has ranged from a low of 12.67 to a high of 23.26. The Medical Distribution industry median ROE % is 7.10. Uniphar's value of 17.29% is 143.5% above this industry median. Based on the distribution chart, Uniphar ranks #28 out of 115 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Uniphar has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Uniphar's ROE % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Uniphar ranks #28 out of 115 companies for ROE %. This places Uniphar in the top 24% of its industry — outperforming the majority of peers. The industry median ROE % is 7.10. Uniphar's value of 17.29% is 143.5% above this benchmark. Historically, Uniphar's own ROE % has ranged from 12.67 to 23.26 over the past decade. While the company's 10-year median is 16.85 vs. the industry median of 7.10, Uniphar has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Distribution company?
The median ROE % among Medical Distribution companies is 7.10, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Uniphar's current ROE % of 17.29% is 143.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Uniphar and its competitors. For the Medical Distribution industry, the median ROE % is 7.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Uniphar's current ROE % is 17.29%, which is near median its own 10-year median of 16.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uniphar stock overvalued right now?
Based on GuruFocus' analysis, Uniphar (DUB:UPR) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.64, compared to a current price of €4.60 — trading 26.4% above its estimated fair value. The current ROE % is 17.29%, which is near median its 10-year median of 16.85 and 143.5% above the Medical Distribution industry median of 7.10. Uniphar's overall GF Score™ is 82/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Uniphar (DUB:UPR), the current ROE % is 17.29% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Uniphar (DUB:UPR) Overvalued in 2026?
Based on GuruFocus' analysis, Uniphar stock appears to be overvalued.
The current stock price of €4.60 is trading 26.4% above its estimated GF Value™ of €3.64.
GuruFocus considers Uniphar to be Modestly Overvalued.
Key valuation signals for DUB:UPR:
ROE %: 17.29% (near median its 10-year median of 16.85)
GF Value™: €3.64 vs. price of €4.60 (26.4% above fair value)
Industry Position: 143.5% above the Medical Distribution median (#28 of 115)
No single metric tells the full story. See the DUB:UPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies.
82GF Score
Get the complete analysis for DUB:UPR
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DUB:UPR has been successfully added to your 
